1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,335 | 0,379 | 11.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SPRINT BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 01.10. | Sprint Bioscience AB: Sprint Bioscience Receives Funding from Vinnova | 384 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ), together with MAX IV, has been awarded approximately SEK 940,000 in funding from Vinnova for a joint research initiative focused on alternative methods for fragment screening... ► Artikel lesen | |
| 26.08. | Sprint Bioscience AB Q2 Loss Increases | 1 | RTTNews | ||
| 23.07. | Sprint Bioscience AB: Sprint Bioscience announces agreement with Lilly TuneLab to accelerate drug development | 436 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announced that it has entered into an agreement with Lilly TuneLab, a collaborative AI-driven drug discovery platform created by Eli Lilly and Company (Lilly). By joining... ► Artikel lesen | |
| 16.04. | Sprint Bioscience AB: Sprint Bioscience completes strategic STK25 evaluation; continued focus on the primary indication | 338 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces the conclusion of a targeted evaluation of the STK25 program, conducted in partnership with the Experimental Drug Development Centre (EDDC), Singapore's national... ► Artikel lesen | |
| 01.04. | Sprint Bioscience AB: Sprint Bioscience appoints Jenni Björnulfson as CFO | 276 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces that Jenni Björnulfson has been appointed chief Financial Officer (CFO) of the company. With extensive and diverse experience in both life science and finance... ► Artikel lesen | |
| 01.04. | Sprint Bioscience AB: Positive results expand the NNMT program into Chronic Kidney Disease | 311 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces positive results from its NNMT program from a proof-of-concept study demonstrating therapeutic potential in Chronic Kidney Disease (CKD). Based on these findings... ► Artikel lesen | |
| 17.03. | Sprint Bioscience AB: Sprint Bioscience reports positive results from the VRK1 program | 411 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces positive results from a pre-clinical proof-of-concept (POC) study performed within the company's VRK1 program. The results show that VRK1 inhibition selectively... ► Artikel lesen | |
| 24.11.25 | Sprint Bioscience Announces Sale Of TREX1 Program to Gilead Sciences | 1.123 | AFX News | FOSTER CITY (dpa-AFX) - Sprint Bioscience AB (SPRINT.ST) announced the sale of its TREX1 cancer program to Gilead Sciences. The deal includes an upfront payment of $14 million, as well as potential... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 7,170 | +2,72 % | This Palatin Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday | ||
| COSCIENS BIOPHARMA | 5,200 | 0,00 % | XFRA ET80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 89,32 | -3,19 % | Halozyme Therapeutics, Inc.: U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE Technology for the Treatment of Advanced Head and Neck Cancer | Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 11,340 | +1,43 % | StoneX raises AbCellera Biologics stock price target to $15 | ||
| GLOW LIFETECH | 0,016 | -5,88 % | Smallcap Discoveries: Glow Lifetech Corp. to Present at the Annual Smallcap Discoveries Conference in Vancouver | Toronto, Ontario--(Newsfile Corp. - September 24, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it will be participating in... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 343,60 | -0,81 % | Bio-Rad reaffirms 2026 currency-neutral revenue growth at (-3%) to 0.5% while targeting non-GAAP operating margin in upper half of 10% to 12% range | ||
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 1,110 | -10,48 % | BioLineRx Ltd.: BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update | - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September -
- Announced new data... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 2,138 | -0,28 % | Minerva Neurosciences, Inc. - 10-Q, Quarterly Report | ||
| WHITEHAWK THERAPEUTICS | 2,700 | -0,74 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights | On track to report initial Phase 1 data from HWK-007 and HWK-016 in 1H'27Initiated Phase 1 trial for HWK-206 in the U.S., the third Whitehawk program to enter the clinic in the last 12 months; HWK-206... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 10,110 | +1,00 % | Abnehmpillen-Boom: Aktie im Plus: Eli Lilly gelingt ein wichtiger Durchbruch | © Foto: Sascha Lotz/dpaEli Lilly sichert sich einen Vorsprung in China. Mit einer neuen Abnehmpille greift der US-Konzern einen Milliardenmarkt an und setzt Novo Nordisk unter Druck Enthaltene Werte:... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,520 | +0,80 % | Ovid Therapeutics GAAP EPS of -$0.10 misses by $0.02 | ||
| GEOVAX LABS | 0,111 | -0,18 % | EQS-News: GeoVax, Inc.: GeoVax Announces 1-for-24 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Announces 1-for-24 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement 09.11.2026 / 14:30 CET/CEST
The... ► Artikel lesen | |
| COCRYSTAL | 0,900 | -5,76 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 8,300 | -2,35 % | Precision BioSciences announces $125M public offering; shares up |
SPRINT BIOSCIENCE AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,351 Euro und damit -5,65 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPRINT BIOSCIENCE AB finden Sie auf Wallstreet Online.